Also listed on Inheris Biopharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Oct 29, 2033 · High confidence
20-year base term ends Oct 29, 2033
Held by Nektar Therapeutics
Filed Apr 29, 2015 as application 14/439,473 · Granted Jun 20, 2017
Base term, 20 years from filing
Today
2013
2033
Clock starts
Oct 29, 2013
Oct 29, 2013
Term ends
Oct 29, 2033
Oct 29, 2033
Granted
Jun 20, 2017
Jun 20, 2017
base term
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 29, 2013, when application PCT/US2013/067273, the earliest non-provisional in its chain, was filed (this one was filed Apr 29, 2015) | Oct 29, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 29, 2033 | High confidence |
This family
| Application PCT/US2013/067273 | PCT application no patent term | no patent term |
| US 9,682,988 | this patent Oct 2033 | Oct 2033 |
| Application 15/498,308 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 2, 2015 Reel 35767, frame 695 | Nektar Therapeutics | Wells Fargo Bank, National Association, as Collateral Agent | Security Interest |
| Oct 6, 2015 Reel 36796, frame 562 | Nektar Therapeutics | TC Lending, LLC, as Collateral Agent | Grant of Security Interest in United States Patents |
| Oct 14, 2015 Reel 36855, frame 686 | Wells Fargo Bank, National Association, as Collateral Agent | Nektar Therapeutics | Release of Security Interest Recorded at Reel 35767, Frame 0695 |
| Mar 29, 2017 Reel 41784, frame 1 | Gadiraju, Ramakrishna; Kowalczyk, Bruce Andrew; Kuklis, Gabriel Christian | Nektar Therapeutics | Assignment of Assignor's Interest |
| Mar 29, 2017 Reel 41784, frame 136 | Andres, Patricia; Datar, Yogesh | Amri Ssci, LLC | Assignment of Assignor's Interest |
| Mar 30, 2017 Reel 41801, frame 707 | Amri Ssci, LLC | Nektar Therapeutics | Assignment of Assignor's Interest |
| Apr 12, 2017 Reel 41982, frame 433 | Mirmehrabi, Mahmoud; Paschalides, Nicholas | Johnson Matthey Pharmaceutical Materials, Inc. D/B/A Johnson Matthey Pharma Services | Assignment of Assignor's Interest |
| Apr 20, 2017 Reel 42084, frame 318 | Johnson Matthey Pharmaceutical Materials, Inc. D/B/A Johnson Matthey Pharma Services | Nektar Therapeutics | Assignment of Assignor's Interest |
| Oct 28, 2019 Reel 50846, frame 461 | Nektar Therapeutics | Inheris Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Oct 28, 2019 Reel 50846, frame 940 | Inheris Pharmaceuticals, Inc. | TC Lending, LLC, as Collateral Agent | Security Interest |
| Nov 15, 2019 Reel 51038, frame 585 | Inheris Pharmaceuticals, Inc. | Inheris Biopharma, Inc. | Change of Name |
| Apr 17, 2020 Reel 52435, frame 62 | TC Lending, LLC, as Collateral Agent | Inheris Biopharma, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 53180, frame 9 | TC Lending, LLC, as Collateral Agent | Nektar Therapeutics | Release of Security Interest |
| Jan 9, 2023 Reel 62313, frame 501 | Inheris Biopharma, Inc. | Nektar Therapeutics | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2033
Term ends Oct 29, 2033. Maintenance fees still fall due before then
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2017 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.